Arcus Biosciences Advances Phase 1 Study for Cancer Treatment

Arcus Biosciences ((RCUS)) announced an update on their ongoing clinical study.

Arcus Biosciences is conducting a Phase 1 study titled A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors. The study aims to evaluate the safety and tolerability of casdatifan, both as a standalone treatment and in combination with cabozantinib or zimberelimab, in patients with advanced solid tumors and clear cell renal cell carcinoma (ccRCC). This study is significant as it explores new therapeutic options for challenging cancer types.

The study tests casdatifan, an experimental drug administered orally, either alone or combined with cabozantinib or zimberelimab. These interventions are designed to assess their effectiveness and safety in treating ccRCC and other solid tumors.

This interventional study follows a non-randomized, sequential model with no masking, focusing primarily on treatment. It involves dose escalation and expansion phases to determine the optimal dosing and safety profile of the interventions.

The study began on October 26, 2022, with a primary completion date yet to be announced. The latest update was submitted on July 29, 2025, indicating ongoing recruitment and progress. These dates are crucial for tracking the study’s development and potential market impact.

This study update could influence Arcus Biosciences’ stock performance as positive results may boost investor confidence and market valuation. The study’s progress is also relevant in the context of competitive cancer treatment developments, potentially affecting industry dynamics.

The study is currently recruiting, with further details available on the ClinicalTrials portal.